Significant transformation often becomes apparent after 3-6 months of consistent treatment
A meta-analysis of 30 studies has confirmed that these increases, although transient and manageable in controlled settings, occur across all dose ranges [106]
The boxed-warning row is the one most often misread
Its targeted effects make it a promising adjunct therapy for metabolic and hormonal imbalances (4)
AOD9604 stimulates lipolysis and inhibits lipogenesis without inducing IGF-1, making it a safer alternative for fat loss without growth promotion. Ng et al., Obesity Research & Clinical Practice Initially developed by Metabolic Pharmaceuticals in Australia, AOD9604 was studied for obesity treatment and has since been embraced by anti-aging clinics and performance-focused users for localized fat reduction, metabolic support, and recovery assistance especially in people who want to avoid the risks of hGH or stimulants
References Rosenstock J, et al